In patients who developed resistance by transforming to small‐cell lung cancer (SCLC), we identified TP53 mutations, one of the key drivers of SCLC, and SCLC‐specific copy number events in plasma before the transformation. This evidence concerns the gene TP53 and small cell lung carcinoma.